Display options
Cite
Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag. 2008;4(1):213-8doi: 10.2147/tcrm.s1771.
Robati, M., Holtz, D., & Dunton, C. J. (2008). A review of topotecan in combination chemotherapy for advanced cervical cancer. Therapeutics and clinical risk management, 4(1), 213-8. https://doi.org/10.2147/tcrm.s1771
Robati, Minoo, et al. "A review of topotecan in combination chemotherapy for advanced cervical cancer." Therapeutics and clinical risk management vol. 4,1 (2008): 213-8. doi: https://doi.org/10.2147/tcrm.s1771
Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag. 2008 Feb;4(1):213-8. doi: 10.2147/tcrm.s1771. PMID: 18728710; PMCID: PMC2503656.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2008 Feb;4(1):213-8. doi: 10.2147/tcrm.s1771.

A review of topotecan in combination chemotherapy for advanced cervical cancer.

Therapeutics and clinical risk management

Minoo Robati, David Holtz, Charles J Dunton

Affiliations

  1. Department of Obstetrics and Gynecology, Main Line Gynecologic Oncology, Lankenau Hospital Wynnewood, PA, USA.

PMID: 18728710 PMCID: PMC2503656 DOI: 10.2147/tcrm.s1771

Abstract

Treatment of advanced, recurrent or persistent cervical cancer includes radiotherapy and chemotherapy. Radiation has been the primary treatment modality for locoregionally advanced cervical cancer. Concomitant systemic cisplatin chemotherapy and radiation have shown high response rates with improvements in durable remissions and overall survival. Cisplatin has been the standard medication for the treatment of advanced cervical cancer. Combinations with other chemotherapeutic agents have been the subject of clinical trials with varying results. The toxicity of combination chemotherapy and tolerability of patients are other factors that should be considered in the management of patients with advanced disease. Recently topotecan, in combination with cisplatin, achieved increased response and overall survival rates without further compromising the patients' quality of life. This review focuses on the mechanism of action and toxicities of topotecan, as well as its role as a radio-sensitizer and chemotherapeutic agent in the management of advanced, recurrent, or persistent cervical cancer. Other combination modalities and dosages are also discussed.

Keywords: advanced cervical cancer; combination chemotherapy; topotecan

References

  1. Int J Gynecol Cancer. 2006 May-Jun;16(3):1157-64 - PubMed
  2. Gynecol Oncol. 2006 Feb;100(2):385-8 - PubMed
  3. J Clin Oncol. 1995 Jul;13(7):1768-76 - PubMed
  4. Br J Cancer. 1997;76(12):1636-9 - PubMed
  5. N Engl J Med. 1999 Apr 15;340(15):1137-43 - PubMed
  6. Gynecol Oncol. 2002 Apr;85(1):89-94 - PubMed
  7. Am J Clin Oncol. 2002 Oct;25(5):496-501 - PubMed
  8. Expert Opin Pharmacother. 2007 Feb;8(2):227-36 - PubMed
  9. Gynecol Oncol. 2000 Oct;79(1):64-6 - PubMed
  10. J Clin Oncol. 1999 May;17(5):1339-48 - PubMed
  11. J Clin Oncol. 2005 Jul 20;23(21):4617-25 - PubMed
  12. Anticancer Drugs. 2005 Oct;16(9):901-9 - PubMed
  13. N Engl J Med. 1999 Apr 15;340(15):1144-53 - PubMed
  14. Gynecol Oncol. 2004 Feb;92(2):635-8 - PubMed
  15. Gynecol Oncol. 2002 Apr;85(1):185-7 - PubMed
  16. Int J Gynecol Cancer. 2000 Jul;10(4):285-288 - PubMed
  17. J Clin Oncol. 2005 Jul 20;23(21):4626-33 - PubMed
  18. Ann Oncol. 1999 Oct;10(10):1171-4 - PubMed
  19. J Clin Oncol. 2000 Apr;18(8):1606-13 - PubMed
  20. N Engl J Med. 1999 Apr 15;340(15):1154-61 - PubMed
  21. Gynecol Oncol. 2000 Jun;77(3):446-9 - PubMed
  22. J Clin Oncol. 1994 Mar;12(3):553-9 - PubMed
  23. Int J Gynecol Cancer. 2006 May-Jun;16(3):1165-71 - PubMed
  24. Oncology (Williston Park). 2006 Oct;20(11):1401-4, 1410; discussion 1410-11, 1415-6 - PubMed
  25. Cancer Chemother Pharmacol. 2001 Jun;47(6):473-80 - PubMed
  26. Gynecol Oncol. 2001 Feb;80(2):128-31 - PubMed
  27. CA Cancer J Clin. 2007 Jan-Feb;57(1):7-28 - PubMed
  28. Gynecol Oncol. 2004 Aug;94(2):483-7 - PubMed
  29. Int J Gynecol Cancer. 2006 May-Jun;16(3):1152-6 - PubMed
  30. Gynecol Oncol. 2003 Sep;90(3 Pt 2):S16-21 - PubMed
  31. J Clin Oncol. 2004 Aug 1;22(15):3113-9 - PubMed
  32. Clin Adv Hematol Oncol. 2006 Apr;4(4):279-86 - PubMed
  33. Semin Oncol. 1997 Dec;24(6 Suppl 20):S20-3-S20-10 - PubMed
  34. J Clin Oncol. 1997 Jan;15(1):165-71 - PubMed
  35. Gynecol Oncol. 2001 May;81(2):213-5 - PubMed

Publication Types